PL2300462T3 - Makrocykliczne pochodne mocznika i sulfonamidu jako inhibitory TAFIa - Google Patents

Makrocykliczne pochodne mocznika i sulfonamidu jako inhibitory TAFIa

Info

Publication number
PL2300462T3
PL2300462T3 PL09757185T PL09757185T PL2300462T3 PL 2300462 T3 PL2300462 T3 PL 2300462T3 PL 09757185 T PL09757185 T PL 09757185T PL 09757185 T PL09757185 T PL 09757185T PL 2300462 T3 PL2300462 T3 PL 2300462T3
Authority
PL
Poland
Prior art keywords
tafia
inhibitors
sulfamide derivatives
macrocyclic urea
macrocyclic
Prior art date
Application number
PL09757185T
Other languages
English (en)
Polish (pl)
Inventor
Christopher Kallus
Mark Broenstrup
Andreas Evers
Anja Globisch
Herman Schreuder
Michael Wagner
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PL2300462T3 publication Critical patent/PL2300462T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL09757185T 2008-06-06 2009-05-22 Makrocykliczne pochodne mocznika i sulfonamidu jako inhibitory TAFIa PL2300462T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06
PCT/EP2009/003650 WO2009146802A1 (de) 2008-06-06 2009-05-22 Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia
EP09757185.5A EP2300462B1 (de) 2008-06-06 2009-05-22 Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia

Publications (1)

Publication Number Publication Date
PL2300462T3 true PL2300462T3 (pl) 2014-10-31

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09757185T PL2300462T3 (pl) 2008-06-06 2009-05-22 Makrocykliczne pochodne mocznika i sulfonamidu jako inhibitory TAFIa

Country Status (34)

Country Link
US (5) US8580777B2 (enExample)
EP (1) EP2300462B1 (enExample)
JP (1) JP5531011B2 (enExample)
KR (1) KR101673886B1 (enExample)
CN (1) CN102056922B (enExample)
AR (1) AR072007A1 (enExample)
AU (1) AU2009254257B2 (enExample)
BR (1) BRPI0913349A2 (enExample)
CA (1) CA2726554C (enExample)
CL (1) CL2009001358A1 (enExample)
CO (1) CO6321271A2 (enExample)
CR (1) CR11807A (enExample)
CY (1) CY1115604T1 (enExample)
DK (1) DK2300462T3 (enExample)
DO (1) DOP2010000363A (enExample)
EC (1) ECSP10010655A (enExample)
ES (1) ES2494390T3 (enExample)
HN (1) HN2010002558A (enExample)
HR (1) HRP20140787T1 (enExample)
IL (1) IL209772A (enExample)
MA (1) MA32322B1 (enExample)
MX (1) MX2010012793A (enExample)
NI (1) NI201000203A (enExample)
NZ (1) NZ589671A (enExample)
PL (1) PL2300462T3 (enExample)
PT (1) PT2300462E (enExample)
RU (1) RU2502736C2 (enExample)
SI (1) SI2300462T1 (enExample)
SV (1) SV2010003747A (enExample)
TW (1) TWI455928B (enExample)
UA (1) UA104002C2 (enExample)
UY (1) UY31868A (enExample)
WO (1) WO2009146802A1 (enExample)
ZA (1) ZA201007719B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012793A (es) 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
CA2727925A1 (en) 2008-06-23 2009-12-30 Astrazeneca Ab New heterocyclic carboxamides for use as thrombin inhibitors
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
AU749132B2 (en) 1997-08-28 2002-06-20 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
MX2010012793A (es) 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.

Also Published As

Publication number Publication date
IL209772A (en) 2016-04-21
NI201000203A (es) 2011-09-29
BRPI0913349A2 (pt) 2015-11-24
ECSP10010655A (es) 2011-01-31
RU2010154089A (ru) 2012-07-20
US20110178130A1 (en) 2011-07-21
KR101673886B1 (ko) 2016-11-08
RU2502736C2 (ru) 2013-12-27
IL209772A0 (en) 2011-02-28
ZA201007719B (en) 2011-07-27
CR11807A (es) 2011-02-16
CA2726554C (en) 2015-02-24
SV2010003747A (es) 2011-03-15
MX2010012793A (es) 2010-12-14
AR072007A1 (es) 2010-07-28
HRP20140787T1 (hr) 2014-11-21
US8722655B2 (en) 2014-05-13
WO2009146802A1 (de) 2009-12-10
JP5531011B2 (ja) 2014-06-25
US20140039011A1 (en) 2014-02-06
CL2009001358A1 (es) 2009-11-27
KR20110020795A (ko) 2011-03-03
DK2300462T3 (da) 2014-08-18
HN2010002558A (es) 2012-08-28
AU2009254257B2 (en) 2013-11-21
JP2011521981A (ja) 2011-07-28
EP2300462B1 (de) 2014-05-21
CN102056922B (zh) 2013-11-20
AU2009254257A1 (en) 2009-12-10
HK1152936A1 (en) 2012-03-16
US20140206760A1 (en) 2014-07-24
US9688645B2 (en) 2017-06-27
SI2300462T1 (sl) 2014-09-30
MA32322B1 (fr) 2011-05-02
TW201008917A (en) 2010-03-01
EP2300462A1 (de) 2011-03-30
NZ589671A (en) 2012-03-30
US9309207B2 (en) 2016-04-12
US20160024033A1 (en) 2016-01-28
TWI455928B (zh) 2014-10-11
DOP2010000363A (es) 2010-12-15
UA104002C2 (ru) 2013-12-25
CA2726554A1 (en) 2009-12-10
US9126955B2 (en) 2015-09-08
UY31868A (es) 2010-01-05
ES2494390T3 (es) 2014-09-15
PT2300462E (pt) 2014-08-05
CN102056922A (zh) 2011-05-11
US8580777B2 (en) 2013-11-12
CO6321271A2 (es) 2011-09-20
US20160251324A1 (en) 2016-09-01
CY1115604T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
IL207731A0 (en) Heterocyclic urea derivatives and methods of use thereof-211
IL209772A (en) Macrocyclic urea derivatives and sulfonamide derivatives as tafia inhibitors
ZA200805648B (en) Substituted imidazole derivatives and their use as PTPase inhibitors
IL210412A0 (en) Heterocyclic derivatives and uses thereof
ZA201104467B (en) Heterocyclic compounds and methods of use
IL214226A (en) Inhibitors of beta-secretase and various related aspects thereof
IL209282A0 (en) Heterocyclic compound and use thereof
EP2480081A4 (en) Bridged heterocyclic compounds and methods for their use
IL192906A0 (en) Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
ZA201008609B (en) Heterocyclic urea derivatives and methods of use thereof
IL212070A (en) Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
SI2379096T1 (sl) Zaviralci TFPI in postopki uporabe
ZA200904109B (en) Aryl sulfamide derivatives and methods of their use
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA201008610B (en) Heterocyclic urea derivatives for the treatment of bacterial infections
ZA200903040B (en) Urea and sulfamide derivatives as tafia inhibitors
GB0918601D0 (en) Decahydro-1H-Indenoquinolinone and decahydro-3H-cyclopenaphenanthridinone CYP17 inhibitors
HUE026577T2 (hu) Imidazol-származékok mint TAFI-a inhibitorok
ZA200806294B (en) Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
HK1149262A (en) Heterocyclic urea derivatives and methods of use thereof-211
EP2625167A4 (en) SALTS AND POLYMORPHES OF SULFAMIDE NS3 INHIBITORS
HK1146272A (en) Heterocyclic urea and thiourea derivatives and methods of use thereof
IL198627A0 (en) Pyrimidine derivatives as posh and posh-ap inhibitors